• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表型药理学中表观遗传靶点的药理学相似性研究进展

Insights from pharmacological similarity of epigenetic targets in epipolypharmacology.

机构信息

Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Mexico City 04510, Mexico; PECEM, Facultad de Medicina, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Mexico City 04510, Mexico.

Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Mexico City 04510, Mexico.

出版信息

Drug Discov Today. 2018 Jan;23(1):141-150. doi: 10.1016/j.drudis.2017.10.006. Epub 2017 Oct 14.

DOI:10.1016/j.drudis.2017.10.006
PMID:29038074
Abstract

As the number of compounds tested against epigenetic targets grows, exploration of the possible associations in chemical space among these targets could lead to the identification of new drugs or new designs of epipolypharmacological molecules. Thus, here we review compound-epitarget associations of public databases. Specifically, we explore the structure-multitarget activity relationships and diversity of over 7000 compounds tested against 52 epigenetic-related targets. We found that, whereas inhibitors of histone deacetylases and other epigenetic targets are clustered in the chemical space, the chemical space of inhibitors of different DNA methyltransferases (DNMTs) did not overlap, indicating DNMT selectivity. These and other compound-epitarget relationships discussed here could be useful for both drug repurposing and the rational design of epipolypharmacological compounds.

摘要

随着针对表观遗传靶点的化合物数量的增加,对这些靶点在化学空间中可能存在的关联的探索可能会导致新药物或新型表观多效性分子的设计。因此,在这里我们回顾了公共数据库中的化合物-靶标关联。具体来说,我们探索了超过 7000 种化合物针对 52 个表观遗传相关靶点的结构-多靶活性关系和多样性。我们发现,组蛋白去乙酰化酶和其他表观遗传靶点的抑制剂在化学空间中聚集,而不同 DNA 甲基转移酶(DNMT)抑制剂的化学空间没有重叠,表明 DNMT 具有选择性。这里讨论的这些化合物-靶标关系对于药物再利用和合理设计表观多效性化合物都可能是有用的。

相似文献

1
Insights from pharmacological similarity of epigenetic targets in epipolypharmacology.表型药理学中表观遗传靶点的药理学相似性研究进展
Drug Discov Today. 2018 Jan;23(1):141-150. doi: 10.1016/j.drudis.2017.10.006. Epub 2017 Oct 14.
2
Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.筛选可调节转录组表观遗传调控的化合物:综述
J Biomol Screen. 2011 Dec;16(10):1137-52. doi: 10.1177/1087057111417871. Epub 2011 Oct 14.
3
Multitarget Drugs: an Epigenetic Epiphany.多靶点药物:一种表观遗传学的顿悟。
ChemMedChem. 2016 Jun 20;11(12):1227-41. doi: 10.1002/cmdc.201500394. Epub 2016 Feb 18.
4
Epigenetic drug discovery: a success story for cofactor interference.表观遗传药物研发:共因子干扰的成功案例。
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748). doi: 10.1098/rstb.2017.0069.
5
Design of small molecule epigenetic modulators.小分子表观遗传修饰剂的设计。
Bioorg Med Chem Lett. 2014 Jan 1;24(1):21-32. doi: 10.1016/j.bmcl.2013.11.001. Epub 2013 Nov 13.
6
Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.表观遗传学靶点和药物发现 第二部分:组蛋白去甲基化和 DNA 甲基化。
Pharmacol Ther. 2015 Jul;151:121-40. doi: 10.1016/j.pharmthera.2015.04.001. Epub 2015 Apr 7.
7
Discovery and development of DNA methyltransferase inhibitors using in silico approaches.使用计算机辅助方法发现和开发 DNA 甲基转移酶抑制剂。
Drug Discov Today. 2015 May;20(5):569-77. doi: 10.1016/j.drudis.2014.12.007. Epub 2014 Dec 16.
8
Epigenetic Treatment Options in Urothelial Carcinoma.尿路上皮癌的表观遗传治疗选择
Methods Mol Biol. 2018;1655:289-317. doi: 10.1007/978-1-4939-7234-0_21.
9
Medicinal chemistry insights in the discovery of novel LSD1 inhibitors.新型赖氨酸特异性去甲基化酶1(LSD1)抑制剂发现中的药物化学见解
Epigenomics. 2015;7(8):1379-96. doi: 10.2217/epi.15.86. Epub 2015 Dec 8.
10
Epigenetic molecular recognition: a biomolecular modeling perspective.
ChemMedChem. 2014 Mar;9(3):484-94. doi: 10.1002/cmdc.201300510. Epub 2014 Feb 12.

引用本文的文献

1
7-Aminoalkoxy-Quinazolines from Epigenetic Focused Libraries Are Potent and Selective Inhibitors of DNA Methyltransferase 1.基于表观遗传学靶点文库的 7-烷氧基喹唑啉类化合物是 DNA 甲基转移酶 1 的高效和选择性抑制剂。
Molecules. 2022 Apr 30;27(9):2892. doi: 10.3390/molecules27092892.
2
An pipeline for the discovery of multitarget ligands: A case study for epi-polypharmacology based on DNMT1/HDAC2 inhibition.一种多靶点配体发现的流程:基于DNMT1/HDAC2抑制的表观多药理学案例研究
Artif Intell Life Sci. 2021 Dec;1. doi: 10.1016/j.ailsci.2021.100008. Epub 2021 Sep 12.
3
Editorial: Natural Product Epigenetic Modulators and Inhibitors.
社论:天然产物表观遗传调节剂与抑制剂
Front Pharmacol. 2021 Mar 4;12:651395. doi: 10.3389/fphar.2021.651395. eCollection 2021.
4
Expanding the Structural Diversity of DNA Methyltransferase Inhibitors.拓展DNA甲基转移酶抑制剂的结构多样性
Pharmaceuticals (Basel). 2020 Dec 27;14(1):17. doi: 10.3390/ph14010017.
5
Recent progress on cheminformatics approaches to epigenetic drug discovery.近年来化学生物信息学方法在表观遗传药物发现中的研究进展。
Drug Discov Today. 2020 Dec;25(12):2268-2276. doi: 10.1016/j.drudis.2020.09.021. Epub 2020 Sep 30.
6
Finding Constellations in Chemical Space Through Core Analysis.通过核心分析在化学空间中寻找星座。
Front Chem. 2019 Jul 16;7:510. doi: 10.3389/fchem.2019.00510. eCollection 2019.
7
Activity Landscape and Molecular Modeling to Explore the SAR of Dual Epigenetic Inhibitors: A Focus on G9a and DNMT1.活性景观与分子建模探索双重表观遗传抑制剂的 SAR:以 G9a 和 DNMT1 为重点。
Molecules. 2018 Dec 11;23(12):3282. doi: 10.3390/molecules23123282.
8
Statistical-based database fingerprint: chemical space dependent representation of compound databases.基于统计的数据库指纹:化合物数据库的化学空间依赖性表示。
J Cheminform. 2018 Nov 22;10(1):55. doi: 10.1186/s13321-018-0311-x.
9
Inhibitors of DNA Methyltransferases From Natural Sources: A Computational Perspective.天然来源的DNA甲基转移酶抑制剂:计算视角
Front Pharmacol. 2018 Oct 10;9:1144. doi: 10.3389/fphar.2018.01144. eCollection 2018.
10
Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization.蛋白质赖氨酸甲基转移酶的新型药理学图谱:靶点去孤儿化的关键
J Cheminform. 2018 Jul 21;10(1):32. doi: 10.1186/s13321-018-0288-5.